GSK Pharma Q3 Review: Motilal Oswal Maintains 'Neutral' Stance On The Stock, Hikes Target Price — Here's Why

In addition to vaccines, GSK Pharma would also be introducing innovative drugs to treat endometrial and ovarian cancer. However, the current valuation captures the earnings upside. Maintain Neutral..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. .Motilal Oswal Report.GlaxoSmithKline Pharmaceuticals Ltd. delivered a better-than-expected performance in Q3 FY25, largely driven by robust volume growth in the general medicine segment and a continued scale-up in vaccine offtake. Notably, GSK Pharma strengthened its market share in top brands like Augmentin, Ceftum and T-bact. It also expanded its presence for its respiratory products.We raise our earnings estimates by 2%/5%/7% for FY25/FY26/FY27 to factor in-differentiated launches in cancer therapy,scale-up of vaccine business, enhanced efforts to boost vaccine prospects. We value GSK Pharma at 33 times 12 months forward earnings to arrive at a target price of Rs 2,170.Compared to a 9% Ebitda CAGR over FY22-24, we expect GSK Pharma to deliver a 19% Ebitda CAGR over FY25-27, driven by niche launches, market share gain, and enhanced reach. In addition to vaccines, GSK Pharma would also be introducing innovative drugs to treat endometrial and ovarian cancer. However, the current valuation captures the earnings upside. Maintain Neutral. .Click on the attachment to read the full report:.GSK Pharma Q3 Results: Profit Increases Fivefold, Beats Estimates.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

GSK Pharma Q3 Review: Motilal Oswal Maintains 'Neutral' Stance On The Stock, Hikes Target Price — Here's Why

The current valuation captures the earnings upside. hence Motilal Oswal maintains Neutral rating on SGK Pharma.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP